These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 9815886

  • 21. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
    Cho YS, Kim MK, Tan L, Srivastava R, Agrawal S, Cho-Chung YS.
    Clin Cancer Res; 2002 Feb; 8(2):607-14. PubMed ID: 11839683
    [Abstract] [Full Text] [Related]

  • 22. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
    Rene B, Fosse P, Khelifa T, Jacquemin-Sablon A, Bailly C.
    Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
    [Abstract] [Full Text] [Related]

  • 23. The RI alpha subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells.
    Tortora G, Pepe S, Bianco C, Baldassarre G, Budillon A, Clair T, Cho-Chung YS, Bianco AR, Ciardiello F.
    Oncogene; 1994 Nov; 9(11):3233-40. PubMed ID: 7936647
    [Abstract] [Full Text] [Related]

  • 24. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.
    Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, Hickson ID.
    Cancer Res; 1991 Dec 15; 51(24):6592-5. PubMed ID: 1660343
    [Abstract] [Full Text] [Related]

  • 25. Chemoprevention with protein kinase A RIalpha antisense in DMBA-mammary carcinogenesis.
    Nesterova MV, Cho-Chung YS.
    Ann N Y Acad Sci; 2005 Nov 15; 1058():255-64. PubMed ID: 16394142
    [Abstract] [Full Text] [Related]

  • 26. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.
    Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL.
    Oncogene; 1993 Apr 15; 8(4):933-8. PubMed ID: 8096076
    [Abstract] [Full Text] [Related]

  • 27. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
    Sorensen M, Sehested M, Jensen PB.
    Mol Pharmacol; 1999 Mar 15; 55(3):424-31. PubMed ID: 10051525
    [Abstract] [Full Text] [Related]

  • 28. Regulation of heparin-binding EGF-like growth factor expression in Ha-ras transformed human mammary epithelial cells.
    Martínez-Lacaci I, De Santis M, Kannan S, Bianco C, Kim N, Wallace-Jones B, Wechselberger C, Ebert AD, Salomon DS.
    J Cell Physiol; 2001 Feb 15; 186(2):233-42. PubMed ID: 11169460
    [Abstract] [Full Text] [Related]

  • 29. Enhanced expression of DNA topoisomerase II by recombinant human granulocyte colony-stimulating factor in human leukemia cells.
    Towatari M, Ito Y, Morishita Y, Tanimoto M, Kawashima K, Morishima Y, Andoh T, Saito H.
    Cancer Res; 1990 Nov 15; 50(22):7198-202. PubMed ID: 1699657
    [Abstract] [Full Text] [Related]

  • 30. A novel use for the comet assay: detection of topoisomerase II inhibitors.
    Salti GI, Das Gupta TK, Constantinou AI.
    Anticancer Res; 2000 Nov 15; 20(5A):3189-93. PubMed ID: 11062742
    [Abstract] [Full Text] [Related]

  • 31. Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis.
    Nesterova MV, Cho-Chung YS.
    Clin Cancer Res; 2004 Jul 01; 10(13):4568-77. PubMed ID: 15240549
    [Abstract] [Full Text] [Related]

  • 32. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
    Alper O, Hacker NF, Cho-Chung YS.
    Oncogene; 1999 Sep 02; 18(35):4999-5004. PubMed ID: 10490835
    [Abstract] [Full Text] [Related]

  • 33. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Mar 02; 24(3):591-608. PubMed ID: 14767544
    [Abstract] [Full Text] [Related]

  • 34. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
    Haldane A, Finlay GJ, Baguley BC.
    Oncol Res; 1993 Mar 02; 5(3):133-8. PubMed ID: 8260750
    [Abstract] [Full Text] [Related]

  • 35. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells.
    Kim D, Lee IS, Jung JH, Lee CO, Choi SU.
    Anticancer Res; 1999 Mar 02; 19(5B):4085-90. PubMed ID: 10628358
    [Abstract] [Full Text] [Related]

  • 36. Correlation between DNA topoisomerase II activity and cytotoxicity in pMC540 and merodantoin sensitive and resistant human breast cancer cells.
    Sharma R, Arnold L, Gulliya KS.
    Anticancer Res; 1995 Mar 02; 15(2):295-304. PubMed ID: 7762997
    [Abstract] [Full Text] [Related]

  • 37. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.
    Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R, Wang JC.
    Cancer Res; 1992 Aug 15; 52(16):4467-72. PubMed ID: 1322791
    [Abstract] [Full Text] [Related]

  • 38. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells.
    Funayama Y, Nishio K, Takeda Y, Kubota N, Ohira T, Ohmori T, Ohta S, Ogasawara H, Hasegawa S, Saijo N.
    Anticancer Res; 1993 Aug 15; 13(6A):1981-8. PubMed ID: 8297104
    [Abstract] [Full Text] [Related]

  • 39. Overexpression of the RI alpha subunit of protein kinase A confers hypersensitivity to topoisomerase II inhibitors and 8-chloro-cyclic adenosine 3'5'-monophosphate in Chinese hamster ovary cells.
    North PS, Davies SL, Ciardiello F, Damiano V, Bianco C, Pepe S, Bianco AR, Harris AL, Hickson ID, Tortora G.
    Cancer Res; 1994 Aug 01; 54(15):4123-8. PubMed ID: 7518350
    [Abstract] [Full Text] [Related]

  • 40. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
    Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, Hsieh TS.
    Clin Cancer Res; 2001 Jun 01; 7(6):1497-504. PubMed ID: 11410482
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.